Mylan Laboratories

Mylan is a global pharmaceutical company with market leading positions in generic pharmaceuticals, transdermal technology and unit dose packaged products. We focus on providing an extensive line of affordable, high quality prescription drugs in traditional and innovative dosage forms, and we enjoy a well-deserved reputation for scientific expertise in creating difficult-to-formulate and high-barrier-to-entry generic products. Mylan operates three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories Inc. (all wholly-owned), and has a 71.5% controlling interest in Matrix Laboratories Limited (71.5% owned). Mylan Pharmaceuticals Inc., with locations in Morgantown, W.Va., Caguas, Puerto Rico, and Greensboro, N.C., is a world leader in the research, development, production and marketing of generic pharmaceuticals. Mylan Technologies Inc., located in St. Albans and Swanton, Vt., is a leader in transdermal drug delivery technology and is the largest producer of generic and branded transdermal patches for the U.S. market. UDL Laboratories Inc., with locations in Rockford, Ill., and Sugar Land, Texas, is the top U.S.-supplier of unit dose pharmaceuticals to hospitals and other institutions. Mylan also owns a controlling interest in India-based Matrix Laboratories Limited, which provides Mylan with a platform for global expansion and growth. Matrix is the second largest supplier of active pharmaceutical ingredient (API) sourcing and provides expanded marketing capabilities through Docpharma, a Matrix subsidiary that is a primary marketer of branded generics in Europe. Matrix is a public limited company listed on the Bombay Stock Exchange and the National Stock Exchange of India and currently owns, in whole or in part, 12 other facilities and business units located in India, China and South Africa.

Contact Details: 1500 Corporate Drive Suite 400 Canonsburg PA 15317 United States of America Tel: 724-514-1800 Fax: Email: investor_relations@mylan.com WWW: www.mylan.com/

Loading...

Press Releases on Mylan Laboratories:
Digirad Names Two Veteran Healthcare Executives to Board	20th May, 2009	Digirad Corporation	Steven C. Mendell and Lloyd H. Malchow Join Digirad Board of Directors POWAY, Calif., May 20 /PRNewswire-FirstCall/ -- Digirad Corporation (Nasdaq: DRAD) today announced that it has named veteran
Halo Pharmaceutical Welcomes Dr. George Bobotas as Its Chief Scientific Officer	20th April, 2009	Halo Pharmaceutical	WHIPPANY, N.J., April 20 /PRNewswire/ -- As part of a Research and Development partnership between Halo Pharmaceutical and DeMelleBioPharma, LLC, Dr. George Bobotas joins Halo Pharmaceutical as Chief
Valeant Pharmaceuticals Appoints President of Valeant Pharmaceuticals International	19th March, 2009	Valeant Pharmaceuticals International	ALISO VIEJO, Calif., March 19 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals (NYSE: VRX) today announced that it has appointed Dr. Bhaskar Chaudhuri to the position of President, Valeant
USPTO Confirms Validity of Bystolic(R) Patent	24th November, 2008	Forest Laboratories, Inc.	NEW YORK, Nov. 24, 2008 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) announced today that the U.S. Patent and Trademark Office ("USPTO") has closed prosecution on the
Senator Hillary Clinton Visits Akrimax Pharmaceutical Plant in Rouses Point, NY	5th August, 2008	Akrimax Pharmaceuticals, LLC	ROUSES POINT, N.Y., Aug. 5 /PRNewswire/ -- U.S. Sen. Hillary Rodham Clinton today visited the Akrimax pharmaceutical plant and paid tribute to Akrimax and the employees for their dedication and

BioNews Results for Mylan Laboratories:
Mylan Laboratories Raises Guidance	Individual.com:  Oct 30 2009 3:29AM Matching: mylan laboratories
Four Pharmaceutical Companies Pay $124 Million for Submission of False Claims to Medicaid	Pharmacy Choice:  Oct 30 2009 5:26AM Matching: mylan laboratories
Mylan Swings To 3Q Loss On Medicaid Settlement; Views Beat	Morningstar.com:  Oct 29 2009 12:03PM Matching: mylan laboratories
Mylan Swings To 3Q Loss On Medicaid Settlement; Views Beat	Nasdaq:  Oct 29 2009 11:37AM Matching: mylan laboratories
UPDATE: Mylan Swings To 3Q Loss On Charges; Upgrades 2009 EPS View	Morningstar.com:  Oct 29 2009 5:09PM Matching: mylan laboratories
Promote your company here: BioNewsCast - Press Release Distribution	→View more Mylan Laboratories news.

Mylan Laboratories Clinical Trials:
A Phase II/III Study of Cysteamine (Mercaptoethylamine) and Zidovudine for the Treatment of HIV Disease

Mylan Laboratories (MYL) Financial information Links from Barchart
MYL Quote from from Barchart.com
MYL Chart from from Barchart.com
MYL Profile from from Barchart.com
MYL Opinion from from Barchart.com
→View more Mylan Laboratories finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 3476 times since April 2007, the link to the organisation's website has been followed 403 times

Recent Search Terms used to find this page: mylan pharmaceuticals | mylan pharmaceuticals global marketing | mylan pharmaceuticals new york office | Mylan global offices | mylan pharmaceuticals plant locations | mylan pharmaceuticals new york office | mylan pharmaceuticals global marketing | mylan | mylan pharmaceuticals new york office | mylan chief science office | .

Search for more companies in Canonsburg

Search for more companies in PA

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Mylan Laboratories